

RECEIVED

OCT 02 2003

PATENT

Attorney Docket No.: 02307K-085040US

Client reference No.: 93-239-2

TECH CENTER 1600/2900**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Charo, Israel F.

Application No.: 09/625,573

Filed: July 25, 2000

For: MAMMALIAN MONOCYTE
CHEMOATTRACTANT PROTEIN
RECEPTORS

Examiner: Christopher J. Nichols

Art Unit: 1646

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98**Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on the attached PTO/SB/08A and PTO/SB/08B forms are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information, and no inference should be made that the information and references cited are, or are considered to be material to patentability because they are in this statement. No inference should be made that the information and references cited are prior art merely because they are in this statement.

Charo, Israel F.
Application No.: 09/625,573
Page 2

PATENT

Applicant believes that no fee is required for submission of this statement, since this IDS was previously submitted prior to the first Office Action. However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.


Respectfully submitted,



Brigitte A. Hajos
Reg. No. 50,971

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 415 576-0200
Fax: 650 326-2422

60042371 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Shee

1

3

<i>Complete if Known</i>	
Application Number	09/625,573
Filing Date	July 25, 2000
First Named Inventor	Charo, Israel F.
Art Unit	1646
Examiner Name	Nichols, Christopher J.
Attorney Docket Number	02307K-085040US

U.S. PATENT DOCUMENTS

U.S. PATENT DOCUMENTS				
		Document Number		
Examiner	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document
	AA	US-5,547,854	08-20-1996	Donahoe et al.
	AB	US-5,460,955	10-24-1995	Mosher et al.
	AC	US-5,413,778	05-09-1995	Kunkel et al.


FOREIGN PATENT DOCUMENTS

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (**optional**). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231
60042391.v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/625,573
(use as many sheets as necessary)				Filing Date	July 25, 2000
				First Named Inventor	Charo, Israel F.
				Art Unit	1646
				Examiner Name	Nichols, Christopher J.
Sheet	2	of	3	Attorney Docket Number	02307K-085040US

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AE	ANSUBEL, F.M., <i>Current Protocols in Molecular Biology</i> , Wiley & Sons, New York 1:22-32, pages 6.11.11-6.11.16 (1994).	<input type="checkbox"/>
	AF	CHARO et al, "Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails," <i>PNAS</i> , 91:2752-2756 (1994).	<input type="checkbox"/>
	AG	CUSHING et al., "Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells," <i>PNAS</i> , 87:5134-5138 (1990).	<input type="checkbox"/>
	AH	EDGINGTON, S.M., "Chemokines In Cardiovascular Disease," <i>Bio/Technology</i> , 11:676-681 (1993).	<input type="checkbox"/>
	AI	FAGGIOTTO et al., "Studies of Hypercholesterolemia in the Nonhuman Primate -I. Changes that Lead to Fatty Streak Formation," <i>Arteriosclerosis</i> , 4(4): 323 - 340 (1984).	<input type="checkbox"/>
	AJ	FURUTANI et al., "Cloning and sequencing of the cDNA for human monocyte chemotactic and activating factor (MCAF)," <i>Biochemical and Biophysical Research Communications</i> , 159(l):249-255 (1989).	<input type="checkbox"/>
	AK	GAO et al., "Structure and functional expression of the human macrophage inflammatory protein 1 α /RANTES receptor," <i>The Journal of Experimental Medicine</i> , 177:1421-1427 (1993).	<input type="checkbox"/>
	AL	GEARING et al., "Expression cloning of a receptor for human granulocyte-macrophage colony-stimulating factor," <i>EMBO J</i> , 8(12): 3667-3676 (1989).	<input type="checkbox"/>
	AM	HOLMES et al., "Structure and functional expression of a human interleukin-8 receptor," <i>Science</i> , 253:1278-1280 (1990).	<input type="checkbox"/>
	AN	JONES et al., "Potential Role of Monocyte Chemoattractant Protein 1/JE in Monocyte/Macrophage-Dependent IgA Immune Complex Alveolitis in the Rat," <i>The Journal of Immunology</i> , 149(6):2147-2154 (1992).	<input type="checkbox"/>
	AO	KOCH et al., "Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis," <i>The Journal of Clinical Investigation</i> , 90:772-779 (1992).	<input type="checkbox"/>
	AP	MURPHY et al., "Cloning of complementary DNA encoding a functional human interleukin-8 receptor," <i>Science</i> , 253:1280-1283 (1991).	<input type="checkbox"/>
	AQ	NELKEN et al., "Monocyte chemoattractant protein-1 in human atheromatous plaques," <i>J Clin. Invest.</i> , 88:1121-1127 (1991).	<input type="checkbox"/>
	AR	NEOTE et al., "Molecular cloning, functional expression, and signaling characteristics of a C-C Chemokine Receptor," <i>Cell</i> , 72:415-425 (1993).	<input type="checkbox"/>
	AS	OPPENHEIM et al. "Properties of the Novel Proinflammatory Supergene 'Intercrine' Cytokine Family," <i>Annual Review of Immunology</i> , 9:617-648 (1991).	<input type="checkbox"/>
	AT	REECK et al., "Homology in Proteins and Nucleic Acids: A Terminology Muddle and a Way out of it," <i>Cell</i> , 50:667 (1987).	<input type="checkbox"/>
	AU	ROLLINS et al., "Suppression of tumor formation in vivo by expression of the JE gene in malignant cells," <i>Molecular and Cellular Biology</i> , 11(6):3125-3131 (1991).	<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹ EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

² Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	09/625,573
(use as many sheets as necessary)				Filing Date	July 25, 2000
				First Named Inventor	Charo, Israel F.
				Art Unit	1646
				Examiner Name	Nichols, Christopher J.
Sheet	3	of	3	Attorney Docket Number	02307K-085040US

	AV	VAN RIPER et al., "Characterization and Species Distribution of High Affinity GTP-coupled Receptors for Human Rantes and Monocyte Chemoattractant Protein 1," <i>J. Exp. Med.</i> , 177:851-856 (1993).	<input type="checkbox"/>
	AW	WALTER et al., "Macrophage Infiltration and Growth of Sarcoma Clones Expressing Different Amounts of Monocyte Chemoattractant Protein/JE," <i>Int. J. Cancer</i> , 49:431-435 (1991).	<input type="checkbox"/>
	AX	WANG et al., "Identification of RANTES Receptors on Human Monocytic Cells: Competition for Binding and Desensitization by Homologous Chemotactic Cytokines," <i>The Journal of Experimental Medicine</i> , 177:699-705 (1993).	<input type="checkbox"/>
	AY	WATSON, eds. <i>The G-Protein Linked Receptor - Facts Book</i> , London, Academic Press (1994) Introduction, pp. 2-6.	<input type="checkbox"/>
	AZ	WOLPE et al., "Macrophage inflammatory proteins 1 and 2: members of a novel superfamily of cytokines," <i>The FASEB Journal</i> , 3:2565-2573 (1989).	<input type="checkbox"/>
	BA	YAMAGAMI et al., "cDNA cloning and functional expression of a human monocyte chemoattractant protein 1 receptor," <i>Biochem. Biophys. Res. Com.</i> , 202(2):1156-1162 (1994).	<input type="checkbox"/>
	BB	YLA-HERTTUALA et al. "Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions," <i>PNAS</i> , 88:5252-5256 (1991).	<input type="checkbox"/>
	BC	YOSHIMURA et al., "Identification of High Affinity Receptors for Human Monocyte Chemoattractant Protein-1 on Human Monocytes," <i>J. Immunology</i> , 145(1): 292-297 (1990).	<input type="checkbox"/>
	BD	YOSHIMURA et al., "Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants," <i>The Journal of Experimental Medicine</i> , 169:1449-1459 (1989).	<input type="checkbox"/>


Examiner Signature		Date Considered
--------------------	--	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60042391 v1



1646
1647

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

RECEIVED

TRANSMITTAL FORM


(to be used for all correspondence after initial filing)

		Application Number	09/625,573
		Filing Date	July 25, 2000
		First Named Inventor	Charo, Israel R.
		Art Unit	1646
		Examiner Name	Christopher J. Nichols
Total Number of Pages in This Submission		Attorney Docket Number	02307K-085040US

ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/ Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s)	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) <i>(please identify below):</i> Return Postcard
		Remarks The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm or Individual	Townsend and Townsend and Crew LLP Brigitte A. Hajos	
Signature		
Date	September 26, 2003	

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.

Typed or printed name	Kristi Coplin		
Signature		Date	September 26, 2003

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.